

## Special Issue

# Novel Prophylactic and Therapeutic Strategies against Respiratory Viral Pathogens for Human and Animal Health

### Message from the Guest Editors

Despite great progress in the development of effective anti-viral strategies, respiratory infections caused by viruses, including orthomyxoviruses, paramyxoviruses, pneumoviruses, coronaviruses, herpesviruses and arteriviruses, are still responsible for serious clinical and economic issues in animal and human health. Thus, novel therapeutics and vaccine strategies are urgently needed to fight circulating viruses and anticipate the constant risk of the emergence or re-emergence of new or already-existing viral strains with pandemic potential. In this Special Issue, we invite you to submit research articles and reviews on innovative prophylactic and therapeutic strategies to combat respiratory viral pathogens, including viruses targeted by the “One Health” approach. Topics of interest include, but are not limited to, new vaccine methods such as the development of universal vaccine candidates, the rational design of adjuvants and delivery systems particularly suitable for mucosal immunization, and alternative approaches for active immunization such as the use of broadly neutralizing antibodies.

---

### Guest Editors

Dr. Christophe Chevalier

Dr. Cynthia Calzas

Prof. Dr. Denis Archambault

Dr. Delphyne Descamps

---

### Deadline for manuscript submissions

closed (20 May 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.4**  
**CiteScore 9.9**  
**Indexed in PubMed**



[mdpi.com/si/64306](https://mdpi.com/si/64306)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).